Advanced search
Publication Cover
Journal of Chemotherapy Volume 36, 2024 - Issue 2
Submit an article Journal homepage
71
Views
0
CrossRef citations to date
0
Altmetric
Antimicrobial Original Research Papers

Effectiveness of remdesivir-based therapy for moderate COVID-19: comparison of Omicron and other variant phases

Atsushi Suzukia Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan;b Department of Internal Medicine, Aichi Prefectural Hospital, Okazaki, Aichi, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8087-1804View further author information
ORCID Icon,
Kensuke Fukumitsub Department of Internal Medicine, Aichi Prefectural Hospital, Okazaki, Aichi, Japan;c Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, JapanView further author information
,
Jun Fukiharab Department of Internal Medicine, Aichi Prefectural Hospital, Okazaki, Aichi, Japan;d Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Aichi, JapanView further author information
,
Takuma Katanob Department of Internal Medicine, Aichi Prefectural Hospital, Okazaki, Aichi, Japan;e Department of Respiratory Medicine and Allergology, Aichi Medical University, Nagakute, Aichi, JapanView further author information
,
Hisashi Kakob Department of Internal Medicine, Aichi Prefectural Hospital, Okazaki, Aichi, Japan;f Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, JapanView further author information
,
Yuri Maedab Department of Internal Medicine, Aichi Prefectural Hospital, Okazaki, Aichi, Japan;f Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, JapanView further author information
,
Makoto Ishiia Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, JapanView further author information
,
Akio Niimic Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, JapanView further author information
,
Kazuyoshi Imaizumif Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, JapanView further author information
&
Etsuro Yamaguchib Department of Internal Medicine, Aichi Prefectural Hospital, Okazaki, Aichi, Japan;e Department of Respiratory Medicine and Allergology, Aichi Medical University, Nagakute, Aichi, JapanView further author information
 show all
Pages 127-132 | Received 27 Dec 2022, Accepted 27 Nov 2023, Published online: 03 Dec 2023
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

Remdesivir is an antiviral drug for the treatment of coronavirus disease 2019 (COVID-19), and the sustained antiviral activity against Omicron variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been reported. In this single-center retrospective study, we first compared the clinical effectiveness of remdesivir-based therapy between Omicron and other variant phases of moderate COVID-19 in a real-world setting. Between Dec 2020 and July 2022, a total of 406 patients with COVID-19 pneumonia were treated with remdesivir-based therapy on admission. The oxygen deterioration rate after initiation of treatment significantly decreased in the Omicron variant phase compared to the alpha and delta variant phases. In an adjusted multivariate Cox proportional hazards model, Omicron variant phase was significantly associated with delayed oxygen deterioration and early recovery from hypoxia. These favorable outcomes during the Omicron variant phase, compared to previous variant phases, might be due to the attenuation and the popularization of vaccination.

Acknowledgments

The authors gratefully acknowledge all participants of this study.

Disclosure statement

AS reports lecture fees from Boehringer Ingelheim and GSK. KF reports research grants from Novartis Pharma and GSK, and lecture fees from AstraZeneca, Boehringer Ingelheim, Novartis Pharma, and Kyorin Pharmaceutical Co., Ltd. JF reports lecture fees from Boehringer Ingelheim and AstraZeneca. TK reports lecture fees from Boehringer Ingelheim, Asahi Kasei Pharma, and Chugai Pharmaceutical Co., Ltd. Other authors have no conflicts of interest to report.

Data availability statement

All data generated or analyzed during this study was included in published article.

Additional information

Funding

There is no funding to report for this submission.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 440.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.